Oscotec Inc. (KOSDAQ:039200)

South Korea flag South Korea · Delayed Price · Currency is KRW
53,900
-1,500 (-2.71%)
Apr 28, 2026, 3:30 PM KST
85.22%
Market Cap 2.06T
Revenue (ttm) 99.84B
Net Income (ttm) 52.34B
Shares Out 38.26M
EPS (ttm) 1,368.00
PE Ratio 39.40
Forward PE 64.09
Dividend n/a
Ex-Dividend Date n/a
Volume 218,579
Average Volume 241,979
Open 54,200
Previous Close 55,400
Day's Range 52,900 - 54,500
52-Week Range 25,000 - 66,000
Beta 1.31
RSI 52.59
Earnings Date May 12, 2026

About Oscotec

Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials... [Read more]

Sector Healthcare
Founded 1998
Employees 53
Stock Exchange KOSDAQ
Ticker Symbol 039200
Full Company Profile

Financial Performance

In 2025, Oscotec's revenue was 99.84 billion, an increase of 193.58% compared to the previous year's 34.01 billion. Earnings were 52.34 billion, an increase of 5871.65%.

Financial Statements

News

There is no news available yet.